The U.S. Food and Drug Administration approved Eli Lilly’s Mounjaro (tirzepatide) to reduce the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke in adults with type 2 diabetes who have established heart disease or elevated cardiovascular risk, making it the first dual GIP/GLP-1 receptor agonist cleared for that purpose in the United States. The decision rested on SURPASS-CVOT, a 13,299-patient outcomes trial across 30 countries that compared Mounjaro with Trulicity and found an 8% lower rate of major adverse cardiovascular events, meeting non-inferiority though not statistical superiority; a separate company-cited analysis showed a 16% reduction in all-cause mortality. Already the most prescribed branded adult type 2 diabetes medicine in the U.S. and a major growth engine alongside obesity drug Zepbound, Mounjaro posted $9.94 billion in second-quarter global revenue, and the expanded label strengthens Lilly’s case for insurance coverage versus weight-loss-only use while intensifying competition with Novo Nordisk’s GLP-1 franchise.